Daily Financial News:
"Science and Technology Innovation Board (STAR Market) shares surged 125.4% in less than an hour after listing, finally welcoming a leading stock."
On October 8, 2021, Kechuang Bio (*****.SH) was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. As of now, Kechuang Bio is trading at RMB 2,295.09 per share, up 125.4%. On its first day of trading, the stock price surged by more than 100% during the opening auction. As the "first stock in brain-computer interface and innovative drugs", Kechuang Bio has set a record for the highest market capitalization of a newly listed stock in the A-share market this year.
Kechuang Bio has the highest offering price in the history of A-shares, requiring more than 500,000 yuan to win a single lot.
To date, users who won the lottery for Kechuang Bio have earned over 500,000 yuan per lot, making it the most profitable new stock in the history of the A-share market.
Kechuang Bio is a biopharmaceutical R&D company that provides patent licensing for brain-computer interface chips, manufacturing of α-endorphins, and patent licensing.
Since its establishment, the company has achieved groundbreaking technological innovations in innovative drugs and brain-computer interfaces. It also owns a full set of patents for brain-computer interface chips and patents for the large-scale industrial production of endorphins, and has the capacity for large-scale endorphin production.
The market believes that the company's relatively high offering price and excellent stock performance, despite the overall sluggishness of the biopharmaceutical market, are inseparable from its competitive advantages.
The strategy team at Guotai Junan Securities stated that, from a strategic perspective, the current pharmaceutical market has entered a phase of differentiation: While the industry trend continues and growth potential remains to be realized, they remain optimistic about the biopharmaceutical industry in the medium to long term, but it is necessary to select biopharmaceutical companies with strong competitive advantages and innovative capabilities. Companies like Kechuang Biotech still present investment opportunities.
The leading stock on the main board is Kweichow Moutai, and the leading stock on the ChiNext board is CATL. Previously, investors pinned their hopes on SMIC to become the leading stock on the STAR Market.
However, SMIC, which has been declining continuously, is unlikely to meet expectations. Its market value of less than 400 billion yuan is far from comparable to CATL and Kweichow Moutai.
"Science and Technology Innovation Biotechnology is the leading stock in the metaverse. We expect it to reach 3,000 yuan in the short term, 5,000 yuan in the medium term, and [amount missing] yuan in the long term!"
In the comments section of Daily Financial News, this person is described as someone who's drunk and randomly presses zeros on the calculator.
"Why didn't I win the lottery? (tears) (tears) (tears) I was just one digit short of winning! 500,000 yuan just slipped through my fingers like that! (tears)"
"Zheng Li is truly amazing; his company's valuation is approaching one trillion yuan after only three years of entrepreneurship."
“I don’t think this price is high at all. I bought one to keep for my son.”
"There are still several positive developments for Kechuang Bio that haven't been revealed yet. When will the brain-computer interface technology be sold to Europe and the United States? What is the progress of new drug development? What are the applications of brain-computer interface technology in other fields? What are the potential profit points of combining brain-computer interface technology with VR?"
“800 billion is just the current valuation of Kechuang Bio. If we consider future growth potential, no company in the A-share market can compare with Kechuang Bio.”
"Science and Technology Innovation Biotechnology has a moat comparable to Pien Tze Huang, stronger growth potential than SMIC, and a more attractive net profit margin than Aimeike. This valuation is completely undervalued!"
"When will the A-share market label the biotech innovation sector as a metaverse concept stock? It's not just a pharmaceutical and semiconductor company; it's the purest metaverse concept stock!"
Will trading be suspended today?
If the price of a newly listed stock on the Science and Technology Innovation Board differs from its opening price by more than 30%, it will trigger a trading halt.
"The price is too high. One lot costs more than 200,000 yuan. Small investors can't even think about participating. It's completely concentrated in the hands of institutions."
"For such a large company to rise so dramatically on the first day, it's definitely because institutions are buying in large quantities. Retail investors simply couldn't lift this stock. I personally am very optimistic about the future development of Kechuang Bio."
Whether it's the price, the booming market, or the legendary nature of Kechuang Bio itself, all of these factors have fueled incredibly high levels of discussion among investors.
The stock forum for Kechuang Bio was immediately pushed to the top of the popularity rankings.
...
Kechuang Bio's final closing price was 2408.01 yuan, making it the company with the highest single price in the A-share market at present, and one of only two companies in the A-share market with a share price of more than 2,000 yuan, the other being Kweichow Moutai.
At the celebratory banquet organized by the Science and Technology Innovation Organization that evening, the noisy atmosphere almost seemed to break through the ceiling.
Li Miaomiao didn't drink much; she was a little unaccustomed to the excessive attentiveness of those around her.
Her colleagues were also aware of her relationship with Zheng Li, and none of them dared to show any improper thoughts towards her.
Afterwards, Li Miaomiao asked the driver to take her and Li Shuyao home.
Although Li Shuyao was an intern on the project, she was also invited to the celebration banquet because she is Li Miaomiao's older sister.
Regardless of Li Shuyao's family background, her status as Li Miaomiao's older sister, or her education and appearance, she became the target of pursuit for the men at the celebration banquet.
Many men in finance are unmarried in their thirties, and Li Shuyao is almost the perfect marriage partner for them.
After getting into the back seat, Li Shuyao sat up straight abruptly. "It feels great to become rich overnight, doesn't it?"
Li Miaomiao was startled: "You're not drunk?"
Li Shuyao chuckled, "How much red wine have you drunk? You're far from drunk!"
"From now on, I'll be relying on you. What percentage of the company's market value is approaching one trillion? Zhengli Shares accounts for that percentage."
Li Miaomiao: "Around sixty-three."
Li Shuyao shook her head: "That's really exaggerated. She's only in her early twenties and her net worth is already as high as 500 billion RMB."
"Zuckerberg is nothing special."
"You met Zheng Li, which is like winning a hundred five-million-dollar lottery tickets in a row. You're so lucky. My whole family and friends have benefited from your good fortune."
"This afternoon, someone from CICC told me that I could work in their investment banking department after graduation."
Li Miaomiao was happy for her sister and clapped her hands repeatedly, saying, "Congratulations on getting your wish!"
"CICC is a good platform."
Li Shuyao sighed, "If it were me in the past, I would definitely be very happy and would call my friends to celebrate."
"But now, seeing my younger sister, whom I grew up with, become a billionaire in a single day, I feel like all my efforts are in vain."
“We grew up together and had a good relationship, and we rarely argued, but I still feel jealousy and wonder why it isn’t me.”
"I know this shouldn't be, but it's normal, it's just human nature."
"After experiencing this, I feel like I need to cultivate myself for a while before I can go back to a normal nine-to-five life."
Li Miaomiao smiled and said, "I never expected this before. When Zheng Li and I went to Suzhou to start our business, the best we could hope for was that we could successfully launch and sell endorphins."
"It can keep the company alive and running normally."
"I never imagined that Kechuang Bio could get to where it is today."
Continue read on readnovelmtl.com
